ADVM Research | Milton Maxwell

ADVM

Adverum Biotechnologies, Inc.

4.3600

+0.0000+0%

Dec 9, 9:30:00 AM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

96.26M

P/E (TTM)

Basic EPS (TTM)

-8.57

Dividend Yield

Recent Filings

8-K

Lilly seals Adverum deal

12/9/25Dec 9, 2025

Eli Lilly completed its $3.56 per share cash acquisition of Adverum Biotechnologies on December 9, 2025, after 64% tender acceptance, folding it into a wholly owned subsidiary. Trading halted; board and officers swapped out. CVRs dangle up to $8.91 on milestones. Public float vanishes.

8-K

Ixo-vec cuts injections 90% at 2 years

12/4/25Dec 4, 2025

Adverum released two-year LUNA Phase 2 data on December 4, 2025, showing Ixo-vec slashed mean annualized anti-VEGF injections ~90% in high-need wet AMD patients—from 10 to 1.1 (6E10 dose) and 0.9 (2E11)—while sustaining visual acuity and anatomic control. No new inflammation after week 30 with Phase 3 dose plus local prophylaxis. ARTEMIS Phase 3 hits 110% enrollment tomorrow. Data bolsters durable burden reduction.

8-K

Lease terminated, trial enrolled

11/21/25Nov 21, 2025

Adverum Biotechnologies terminated its Durham, NC lease early on November 19, 2025—originally running to 2037—paying $0.1 million cash and releasing a $7.4 million promissory note at 5% interest maturing by January 2031 or upon $150 million Ixo-vec revenues. Trial hit target. Enrollment complete.

10-Q

Q3 FY2025 results

11/12/25Nov 12, 2025

Adverum posted a Q3 operating loss of $48.0M, up 39% y/y (derived), driven by R&D expenses jumping to $38.9M from $20.4M on Phase 3 Ixo-vec trials, while G&A fell to $9.1M from $15.0M after sublease issues eased. Net loss hit $47.7M or $(2.03) per diluted share on 23.5M shares, versus $(1.55) last year—EPS widens on higher losses, shares up. Cash burned $109.7M YTD to $26.1M, offset by $10M private placement; Lilly merger pending Q4 close offers $65M note bridge. Leases restructured with rent abatement to Feb 2026, $7.4M note escrow. Yet cash won't last without deal. Merger failure risks bankruptcy.

8-K

Lilly acquires Adverum for $3.56 + CVR

10/24/25Oct 24, 2025

Adverum signed a merger deal with Eli Lilly on October 24, 2025, for $3.56 cash per share plus a CVR worth up to $8.91 on Ixo-vec milestones: U.S. approval by year seven and $1B sales by year ten. Lilly offers up to $65M secured note for clinical work, maturing January 22, 2026. Deal closes post-tender if majority shares tender. CVR payouts hinge on regulatory, sales success.

About

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

CEO

Dr. Laurent Fischer M.D.

IPO

7/31/2014

Website

https://adverum.com

Employees

155

Sector

Healthcare

Industry

Biotechnology